All filters
Slidesets
HEV Update: Diagnostics and Management- Kenneth Sherman, MD, PhD
Presented at:
HEP DART 2017
Slidesets
Is There a Best Host Acting Antiviral for HBV Cure?- Jake Liang
Presented at:
HEP DART 2017
Slidesets
Is there a best immunomodulator in development?- Ulrike Protzer
Presented at:
HEP DART 2017
Slidesets
Is there a best Direct Acting Antiviral in development?- Fabien Zoulim, MD, PhD
Presented at:
HEP DART 2017
Slidesets
New directions towards functional cure of Chronic Hepatitis B- Lawrence Blatt, PhD
Presented at:
HEP DART 2017
Slidesets
Looking back to move forward: designing next-gen RNAi for best results in HBV- Bruce Given
Presented at:
HEP DART 2017
Slidesets
SB 9200: A novel RIG-I agonist for chronic hepatitis B- Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Presented at:
HEP DART 2017
Slidesets
Studies of the HBV-immune modulator AIC649 (not yet available)- Helga Rübsamen-schaeff
Presented at:
HEP DART 2017
Slidesets
Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure- Michael Sofia, PhD
Presented at:
HEP DART 2017
Slidesets
Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)- Joseph Doyle, MD
Presented at:
HEP DART 2017
Slidesets
Management of HCV in Decompensated liver disease- Michael Manns
Presented at:
HEP DART 2017
Slidesets
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?- Jordan Feld, MD, MPH
Presented at:
HEP DART 2017
Slidesets
Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination- Tarik Asselah
Presented at:
HEP DART 2017
Slidesets
When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul Pockros
Presented at:
HEP DART 2017
Slidesets
A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization- Dr. N. Mani
Presented at:
HEP DART 2017
Slidesets
NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes- Arun Sanyal
Presented at:
HEP DART 2017
Slidesets
Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors- Dr. B. Cox
Presented at:
HEP DART 2017
Slidesets
Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside (not available)- Michael Fried
Presented at:
HEP DART 2017